The effect of insulin on response to intravitreal anti-VEGF injection in diabetic macular edema in type 2 diabetes mellitus

Rajya L. Gurung; Liesel M. FitzGerald; Ebony Liu; Bennet J. McComish; Georgia Kaidonis; Bronwyn Ridge; Alex W. Hewitt; Brendan Jt Vote; Nitin Verma; Jamie E. Craig; Kathryn P. Burdon

doi:10.1186/s12886-022-02325-x

The effect of insulin on response to intravitreal anti-VEGF injection in diabetic macular edema in type 2 diabetes mellitus

Rajya L. Gurung, Liesel M. FitzGerald, Ebony Liu, Bennet J. McComish, Georgia Kaidonis, Bronwyn Ridge, Alex W. Hewitt, Brendan Jt Vote, Nitin Verma, Jamie E. Craig, Kathryn P. Burdon

College of Medicine and Public Health

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

48 Downloads (Pure)

Abstract

Objectives: To assess whether insulin therapy impacts the effectiveness of anti-vascular endothelial growth factor (anti-VEGF) injection for the treatment of diabetic macular edema (DME) in type 2 diabetes mellitus. Methods: This was a retrospective multi-center analysis. The best-corrected visual acuity (BCVA) at 12 months, BCVA change, central macular thickness (CMT), CMT change, and cumulative injection number were compared between the insulin and the oral hypoglycemic agent (OHA) groups. Results: The mean final BCVA and CMT improved in both the insulin (N = 137; p < 0.001; p < 0.001, respectively) and the OHA group (N = 61; p = 0.199; p < 0.001, respectively). The two treatment groups were comparable for final BCVA (p = 0.263), BCVA change (p = 0.184), final CMT (p = 0.741), CMT change (p = 0.458), and the cumulative injections received (p = 0.594). The results were comparable between the two groups when stratified by baseline vision (p > 0.05) and baseline HbA1c (p > 0.05). Conclusion: Insulin therapy does not alter treatment outcomes for anti-VEGF therapy in DME.

Original language	English
Article number	94
Number of pages	9
Journal	BMC Ophthalmology
Volume	22
Issue number	1
DOIs	https://doi.org/10.1186/s12886-022-02325-x
Publication status	Published - 28 Feb 2022

Keywords

Anti-VEGF
Central macular thickness
Diabetic macular edema
Insulin
Visual acuity

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s12886-022-02325-xLicence: CC BY

Gurung_Effect_P2022Final published version, 1.07 MBLicence: CC BY

Cite this

@article{d11b93e1a0144e4cb3639c74482c6089,

title = "The effect of insulin on response to intravitreal anti-VEGF injection in diabetic macular edema in type 2 diabetes mellitus",

abstract = "Objectives: To assess whether insulin therapy impacts the effectiveness of anti-vascular endothelial growth factor (anti-VEGF) injection for the treatment of diabetic macular edema (DME) in type 2 diabetes mellitus. Methods: This was a retrospective multi-center analysis. The best-corrected visual acuity (BCVA) at 12 months, BCVA change, central macular thickness (CMT), CMT change, and cumulative injection number were compared between the insulin and the oral hypoglycemic agent (OHA) groups. Results: The mean final BCVA and CMT improved in both the insulin (N = 137; p < 0.001; p < 0.001, respectively) and the OHA group (N = 61; p = 0.199; p < 0.001, respectively). The two treatment groups were comparable for final BCVA (p = 0.263), BCVA change (p = 0.184), final CMT (p = 0.741), CMT change (p = 0.458), and the cumulative injections received (p = 0.594). The results were comparable between the two groups when stratified by baseline vision (p > 0.05) and baseline HbA1c (p > 0.05). Conclusion: Insulin therapy does not alter treatment outcomes for anti-VEGF therapy in DME.",

keywords = "Anti-VEGF, Central macular thickness, Diabetic macular edema, Insulin, Visual acuity",

author = "Gurung, {Rajya L.} and FitzGerald, {Liesel M.} and Ebony Liu and McComish, {Bennet J.} and Georgia Kaidonis and Bronwyn Ridge and Hewitt, {Alex W.} and Vote, {Brendan Jt} and Nitin Verma and Craig, {Jamie E.} and Burdon, {Kathryn P.}",

year = "2022",

month = feb,

day = "28",

doi = "10.1186/s12886-022-02325-x",

language = "English",

volume = "22",

journal = "BMC Ophthalmology",

issn = "1471-2415",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - The effect of insulin on response to intravitreal anti-VEGF injection in diabetic macular edema in type 2 diabetes mellitus

AU - Gurung, Rajya L.

AU - FitzGerald, Liesel M.

AU - Liu, Ebony

AU - McComish, Bennet J.

AU - Kaidonis, Georgia

AU - Ridge, Bronwyn

AU - Hewitt, Alex W.

AU - Vote, Brendan Jt

AU - Verma, Nitin

AU - Craig, Jamie E.

AU - Burdon, Kathryn P.

PY - 2022/2/28

Y1 - 2022/2/28

N2 - Objectives: To assess whether insulin therapy impacts the effectiveness of anti-vascular endothelial growth factor (anti-VEGF) injection for the treatment of diabetic macular edema (DME) in type 2 diabetes mellitus. Methods: This was a retrospective multi-center analysis. The best-corrected visual acuity (BCVA) at 12 months, BCVA change, central macular thickness (CMT), CMT change, and cumulative injection number were compared between the insulin and the oral hypoglycemic agent (OHA) groups. Results: The mean final BCVA and CMT improved in both the insulin (N = 137; p < 0.001; p < 0.001, respectively) and the OHA group (N = 61; p = 0.199; p < 0.001, respectively). The two treatment groups were comparable for final BCVA (p = 0.263), BCVA change (p = 0.184), final CMT (p = 0.741), CMT change (p = 0.458), and the cumulative injections received (p = 0.594). The results were comparable between the two groups when stratified by baseline vision (p > 0.05) and baseline HbA1c (p > 0.05). Conclusion: Insulin therapy does not alter treatment outcomes for anti-VEGF therapy in DME.

AB - Objectives: To assess whether insulin therapy impacts the effectiveness of anti-vascular endothelial growth factor (anti-VEGF) injection for the treatment of diabetic macular edema (DME) in type 2 diabetes mellitus. Methods: This was a retrospective multi-center analysis. The best-corrected visual acuity (BCVA) at 12 months, BCVA change, central macular thickness (CMT), CMT change, and cumulative injection number were compared between the insulin and the oral hypoglycemic agent (OHA) groups. Results: The mean final BCVA and CMT improved in both the insulin (N = 137; p < 0.001; p < 0.001, respectively) and the OHA group (N = 61; p = 0.199; p < 0.001, respectively). The two treatment groups were comparable for final BCVA (p = 0.263), BCVA change (p = 0.184), final CMT (p = 0.741), CMT change (p = 0.458), and the cumulative injections received (p = 0.594). The results were comparable between the two groups when stratified by baseline vision (p > 0.05) and baseline HbA1c (p > 0.05). Conclusion: Insulin therapy does not alter treatment outcomes for anti-VEGF therapy in DME.

KW - Anti-VEGF

KW - Central macular thickness

KW - Diabetic macular edema

KW - Insulin

KW - Visual acuity

UR - http://www.scopus.com/inward/record.url?scp=85125545405&partnerID=8YFLogxK

UR - http://purl.org/au-research/grants/NHMRC/1116360

U2 - 10.1186/s12886-022-02325-x

DO - 10.1186/s12886-022-02325-x

M3 - Article

C2 - 35227220

AN - SCOPUS:85125545405

SN - 1471-2415

VL - 22

JO - BMC Ophthalmology

JF - BMC Ophthalmology

IS - 1

M1 - 94

ER -

The effect of insulin on response to intravitreal anti-VEGF injection in diabetic macular edema in type 2 diabetes mellitus

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this